Cannabis statistics Switzerland

How common is cannabis use in Switzerland? The official results used here come from the 2022 Swiss Health Survey. Reviewing this page in 2026 does not make it a new survey. We explain what the figures tell us and where their limits lie.

Consumption, medical treatment, seizures, pilot trials and sales concern different things. Police statistics describe recorded events, surveys describe reported behaviour and project reports describe a particular participant group. These figures cannot be added up to produce a total number of users.

Multiplying a consumption percentage by an assumed price does not establish market revenue. A defensible estimate would need quantities, frequency, price definitions and transparent assumptions, among other inputs. Where those foundations are missing, we do not publish a figure that suggests false precision.

Definition and context

The statistics hub aggregates key figures on the Swiss cannabis market: consumption prevalence, price levels, seizures, market volume, and pilot project data.

The situation in Switzerland

Data sources include the BAG (Federal Office of Public Health) addiction monitoring, police crime statistics, and evaluations from the pilot projects. Our open-data section provides these datasets in CSV and JSON formats so that editorial teams and researchers can use them directly.

What this means in practice

When comparing prices, it is important to consider the channel: clubs, pilot projects, shops, and the street vary widely, meaning average values across all channels are of little significance.

Frequently asked questions

How many people consume cannabis in Switzerland?

The BAG addiction monitoring indicates a scale of several hundred thousand regular users; the exact figures are available in our data section along with the sources.

Am I allowed to quote your data?

Yes. The datasets can be used freely with attribution and are available in CSV and JSON formats.

How often are the figures updated?

With every new publication of the primary source; each dataset includes an 'as of' date.

Background and development

Switzerland's approach to cannabis shifted from strict prohibition to pragmatic, scientific regulation. The Federal Narcotics Act (BetmG) historically criminalized all high-THC cannabis. In 2011, the Federal Assembly set the legal threshold for industrial hemp and low-THC cannabis at one percent total THC, separating it from the strict classification of narcotic hemp. A major scientific milestone occurred in May 2021 with the amendment of Article 8a BetmG, enabling the Federal Office of Public Health (FOPH/BAG) to authorize pilot studies. These trials evaluate the public health and social impacts of regulated sales. Further liberalization followed on 1 August 2022, when the federal government transferred the authorization of medical cannabis from the FOPH to Swissmedic, allowing doctors to prescribe medical THC directly without exceptional permits. Today, Switzerland balances strict administrative enforcement with a research-driven transition towards a state-regulated recreational market, using empirical data from municipal pilot projects to design future national drug policies.

Distinctions and misconceptions

Navigating Swiss cannabis regulations requires correcting common misconceptions. Many assume that possessing under ten grams of cannabis is fully legalized; in truth, it remains illegal under the BetmG but is exempt from prosecution, carrying a one-hundred-franc fixed penalty if caught consuming, without a permanent criminal record. Another frequent error is confusing legal CBD with recreational THC. Only cannabis with less than one percent total THC is legally classified as a non-narcotic commodity. Furthermore, medical cannabis, fully legalized for prescription use on 1 August 2022, operates under a separate regulatory pathway from recreational pilot projects. Finally, the driving limit of 1.5 micrograms of THC per liter of blood constitutes a de facto zero-tolerance policy. Consuming legal CBD can still trigger a positive roadside test if it contains trace THC, highlighting the strict boundary between legal possession limits and road traffic safety laws.

Decision guide for Switzerland

An adult in Switzerland seeking to obtain cannabis legally must navigate three distinct pathways. First, evaluate your eligibility: for medical needs, consult a physician to obtain a standard prescription under Swissmedic rules, utilizing regulated pharmacies. For recreational access, verify if you live in a municipality hosting an active FOPH-approved pilot project, such as Zurich, Basel, Bern, Lausanne, or Geneva, as registration is open to local adult residents. If choosing the commercial market, stick strictly to legal low-THC products containing under one percent THC. Always verify lab certificates to avoid illicit products. Avoid purchasing from black-market street dealers where prices average ten to twelve francs per gram but lack purity testing and run the risk of a one-hundred-franc disciplinary fine. Finally, remember that membership in Swiss cannabis clubs is open to all adults over eighteen, providing a legal platform to access resources, network, and stay informed on regulatory developments.

What is the legal THC limit for driving in Switzerland?

Switzerland enforces a strict limit of 1.5 micrograms of THC per liter of blood, which functions as a zero-tolerance policy. If police suspect impairment, a rapid oral swab or blood test is ordered. Violations lead to heavy fines, license suspension, and potential criminal charges. Drivers should note that even consuming legal CBD can cause trace THC to accumulate and exceed this threshold.

How does the medical cannabis prescription system work since the 2022 reform?

Since 1 August 2022, patients do not require exceptional authorization from the Federal Office of Public Health. Any Swiss-licensed physician can directly prescribe medical cannabis containing over one percent THC. Prescriptions are dispensed through authorized Swiss pharmacies. Patients should consult their doctor regarding treatment plans and contact their health insurance provider directly, as mandatory basic insurance does not automatically cover the costs of these medical treatments.

Explore this topic further

These guides explain the background and address practical questions in the Swiss context.

Key figures

  • 220’000+ — Swiss adults regularly consume cannabis (BAG · Suchtmonitoring 2024)
  • 36% — of 15–34 year-olds have tried cannabis (EMCDDA · Country Report Switzerland 2024)
  • CHF 582M — estimated Swiss cannabis black-market revenue per year (Uni Genf · Cannabis Market Estimate 2023)
  • 7 — cities with active or approved pilot projects (BAG · Cannabis Pilotversuche 2026)

Current research

  • Cannabis use in Switzerland — Addiction Monitoring 2024 — Sucht Schweiz, BAG · 2024
  • European Drug Report — Cannabis Chapter — EMCDDA, EUDA · 2024
  • WHO Expert Committee on Drug Dependence — Cannabis Review — WHO ECDD, WHO · 2023

Datasets on this topic